|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.47 AUD | -2.65% |
|
+0.41% | +93.15% |
| 02:10am | Telix Pharmaceuticals' Revenue Jumps 55% in Q2; Raises Guidance | MT |
| 01:14am | Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024 | CI |
Telix Pharmaceuticals Limited updated earnings guidance for the fiscal year 2024. For the period, company now expects revenue to be in the range of USD 490 million to USD 510 million (AUD 745 million to AUD 776 million at current exchange rates). This represents an approximate increase of 48% to 54% on 2023 revenue.
Prior guidance was ranged at USD 445 million to USD 465 million(AUD 675 million to AUD 705 million).
| 1st Jan change | Capi. | |
|---|---|---|
| +93.15% | 4.5B | |
| +24.74% | 47.54B | |
| -0.47% | 41.96B | |
| +43.96% | 41.55B | |
| +25.40% | 30.36B | |
| +17.96% | 27.61B | |
| -4.47% | 28.7B | |
| +50.73% | 14.7B | |
| +42.56% | 13.51B | |
| +1.46% | 12.34B |
TELIX PHARMACEUTICALS LIMITED 
